Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2016Journal of Oncology Pharmacy Practice

Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBernard L. MariniUniversity of Maryland, BaltimoreDMDenise MarkstromUniversity of MichiganDFDavid FrameUniversity of Michigan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Marini et al. (2016) studied this question.

synapsesocial.com/papers/6a83631f79bf9b810571d3a2https://doi.org/10.1177/1078155216637216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation2010 · 1,503 citations
  2. 2Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation2006 · 154 citations
  3. 3Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody2003 · 199 citations
  4. 4Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis2006 · 565 citations
  5. 5Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis2006 · 325 citations